Cell-Based Flow Cytometry Assay for Neutralizing Antibodies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current enzyme replacement therapies for lysosomal storage diseases face challenges due to the development of enzyme-specific antibodies that can interfere with receptor-mediated enzyme uptake, leading to reduced efficacy and potential adverse events, necessitating reliable assays to measure neutralizing factors.
Innovation Solution
A cell-based flow cytometry method is developed to detect and quantify lysosomal enzyme-specific neutralizing factors by conjugating a detection moiety to the enzyme and using cells expressing the cation-independent mannose 6-phosphate receptor to assess the presence and activity of these factors in patient body fluids.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If enzyme replacement therapy is administered to treat lysosomal storage diseases, then the enzymatic activity is improved, but neutralizing antibodies are generated that interfere with receptor-mediated enzyme uptake
Solution Approach 1:
The patent applies preliminary action by performing a cell-based uptake assay before administering enzyme replacement therapy to predict whether neutralizing antibodies will interfere with therapeutic enzyme uptake. The assay uses patient cells expressing the relevant mannose 6-phosphate receptor and pre-incubates them with the therapeutic enzyme to detect potential neutralizing factors in the patient's body fluid, allowing clinicians to anticipate and prevent therapeutic failure before it occurs.
2Ease of operation
If conventional ELISA-based assays are used to detect neutralizing antibodies, then the detection process is simplified, but the ability to accurately measure functional interference with enzyme uptake is reduced
Solution Approach 1:
The patent uses patient-derived cells expressing the mannose 6-phosphate receptor as an intermediary system to translate the functional effect of neutralizing antibodies into measurable outcomes. These living cells serve as a bridge between the complex immunological interaction (which is difficult to measure directly) and the simple flow cytometry readout, allowing accurate detection of functional neutralization while maintaining operational simplicity through automated flow cytometry analysis.
3Measurement precision
If cell-based flow cytometry methods are used to detect neutralizing factors, then the measurement accuracy of functional interference is improved, but the assay complexity increases
Solution Approach 1:
The patent achieves universality by developing a multi-functional cell-based assay platform that can evaluate multiple therapeutic enzymes and detect various types of neutralizing factors (antibodies, aptamers, other proteins) using a single standardized protocol. The method uses universally applicable components including patient-derived cells, flow cytometry instrumentation, and standardized data analysis, allowing the same assay system to assess functional interference for different enzyme replacement therapies without requiring method development for each specific case.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method allows for accurate measurement of neutralizing factors, enabling better monitoring of treatment efficacy and potential adjustments to therapy, such as immunosuppressive interventions or dose reductions, to enhance the effectiveness of enzyme replacement therapy.
Implementation Method 1
The cation-independent mannose 6-phosphate receptor (CI-MPR) directs uptake of enzyme from blood to tissue and then mediates intracellular routing to the lysosome
Implementation Method 2
A cell-based flow cytometry method is developed to detect and quantify lysosomal enzyme-specific neutralizing factors
Data Source
AI summary
The present invention relates to cell-based methods for screening body fluids or tissues for factors that prevent cellular uptake of lysosomal enzymes, including neutralizing factors such as neutralizing antibodies, that arise as a result of lysosomal enzyme replacement therapy.